OVERVIEW:I was recruited by the Board of Directors and Orbimed Advisors to drive a full-scale turnaround for a biologics company with 8-figure annual revenues as the CEO. In this position, I direct a multi-location operation, lead the executive and management teams, and hold full P&L accountability for results. Using a strategy of sales focus, team building, operations growth, and problem-solving, I assembled a new management team, acquired X-Spine Systems, and restructured all aspects of the existing organization to reverse a prior history of under-performance. I placed a premium on right-sizing an uninspired corporate culture to create a can-do, energetic environment that placed customers first and foremost.HIGHLIGHTS:★ BY THE NUMBERS – Drove revenue growth from $30M to $90M annual total (enterprise value expanded $150M+). Concurrently improved all financial metrics, including a full reversal from a loss to low teens EBITDA in 2017. ★ 180-DEGREE PERFORMANCE TURNAROUND:☑ Implemented professional Sales and Customer Service organization based on a hybrid model, along with aggressive asset management systems that leveraged instrumentation and consigned inventory.☑ Built a National Accounts team to capitalize on shift from GPO to IDN / local contracting and facilitate hospital access.☑ Introduced Portfolio Selling strategy to improve the distribution channel and revenues per transaction.☑ Strengthened cash flow through price increases, collections improvement, and strict expense controls.★ CULTURE TRANSFORMATION – Recast the corporate vision, implemented performance metrics, rebuilt key teams and cultivated existing talent, leveraged key product and distribution differentiators, and rewarded success in all areas to transform the entire culture.★ PRODUCT & PORTFOLIO DEVELOPMENT – Revitalized the flagship brand and launched new configurations for ortho-spine.

As the CEO, I held full P&L responsibility for a company specializing in ultrasonic technologies and related techniques for body sculpting and liposuction solutions. In this role, I was tapped by private equity investors to lead a complete reversal of declining revenues and profits within a highly challenging economic climate. Establishing and managing the turnaround strategy, I recruited and built a leadership team, reengineered the existing operations, and drove business development opportunities that included M&A initiatives, leading to the company’s eventual sale to Solta / Valeant in 2013.HIGHLIGHTS:★ BY THE NUMBERS – Spearheaded revenue increase from $9M to $30M+ annual total while concurrently achieving a positive cash flow, gross margin gain from 40% to 75%, and enterprise value growth from a 7-figure to a mid 8-figure total.★ ORGANIZATIONAL TURNAROUND – Right-sized performance through a multi-pronged approach:☑ Shifted all business and sales models from rentals to capital equipment placement and restructured capitalization to incentivize new investments.☑ Influenced physician value chain, conducted in-field customer needs assessments, coached staff on customer usage patterns, and personalized product marketing / branding.☑ Reenergized sales by redesigning territories, restructuring compensation, and expanding the U.S. team.★ NEW PRODUCT DEVELOPMENT – Facilitated launch of 2nd-generation technology at a higher price point to improve sales and margins. Gained entry into non-invasive procedure market, expanded distribution channels, and established new standards by leading opportunity and product development for 5 new offerings in 3 years.★ STRATEGIC ALLIANCES – Cultivated alliances with 40 global distribution partners. Fostered partnership with Italian company General Project to commercialize product family, enabling access to new U.S. and global markets by negotiating co-marketing and distribution agreements.

I was recruited by the company founder to lead all next-level growth efforts, including restructuring initiatives, and fulfill the founder’s “miniature dialysis device” product vision. As the CEO and President, I held full accountability for an 8-figure annual P&L, oversaw the entire leadership team, and played a critical role in the overarching business plan development and execution. To optimize commercialization efforts, I led all development and deployment activities for portable dialysis products and services. As a key aspect of this effort, I focused on maximizing opportunities with Wall Street investors and cultivating buy-in from the Board of Directors for our portable dialysis product.HIGHLIGHTS:★ SHAREHOLDER VALUE – Positioned the company for 8-figure PIPE financing by orchestrating a reverse merger into a public shell, gaining critical access to capital and propelling development as well as clinical trials for proprietary technology. ☑ Set the stage for a subsequent 5x shareholder value boost, leading to Xcorporeal’s eventual strategic sale to Fresenius.★ PRODUCT COMMERCIALIZATION – Expedited time to market and deepened Wall Street investor support by envisioning, building business case, and capturing consensus from the Board for the portable dialysis product. Additional initiatives included:☑ Penetrated acute care and home use markets by refocusing the company’s business model and product definitions.☑ Recruited, assembled, and led both executive and clinical research teams to drive attainment of mission-critical milestones.

I was recruited by the lead investor to guide the early-stage development for this glucose measurement start-up company. As the CEO, I led all fundraising efforts and built a top-talent executive management team.HIGHLIGHTS:★ BUSINESS DEVELOPMENT – Secured $40M in venture capital funding and captured strategic partnerships with Roche and Panasonic.★ PRODUCT COMMERCIALIZATION – Refined the business model and the product vision to optimize cash flow and validate Glucon’s core technology. Leveraged photoacoustic technology platform to penetrate profitable acute market.☑ Jumpstarted the acute care business, recruiting clinical research staff and leading product/clinical development to meet goals against tight timelines.

As the President, I held full P&L accountability for 3 separate medical companies with total annual revenue of $250M. I directed all functional areas that included Finance, Sales, Marketing, Regulatory Affairs, HR, Customer Fulfillment, IT, and M&A. In this position, I focused efforts on leading restructuring initiatives to address an under-performing operation. HIGHLIGHTS:★ OPERATIONS STREAMLINING – Streamlined operations by integrating over 12 product lines from 4 divergent brands and consolidating multiple business units. Reduced headcount by 20%; rebuilt management and product development teams to strengthen team performance.★ ORGANIZATIONAL REENGINEERING – Aligned business and sales models with corporate objectives; designed and led full-scale company revamp, including reshaping of diverse, international Manufacturing, Sales, and Service units.★ MERGERS / ACQUISITIONS – Identified Spacelabs opportunity and guided successful $200M acquisition.

HIGHLIGHTS:★ FUNDRAISING & BUSINESS GROWTH – Raised 8-figure venture capital funding as the company’s Co-Founder. Tendered partner offers from organizations in the U.S., Europe, and Japan.★ PRODUCT DEVELOPMENT – Served as a Co-Inventor of a non-invasive blood glucose technology.EARLY CAREER EXPERIENCE:General Manager, Oximetry – OhmedaSenior Engineering Manager – NellcorProduct Development Engineer – HP